%0 Journal Article
%T Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
%A Ken LaPensee
%A Thomas Lodise
%J Archive of "American Health & Drug Benefits".
%D 2018
%X Omadacycline is an oral and intravenous (IV) once-daily aminomethylcycline antibiotic that was recently approved by the US Food and Drug Administration for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). In 2 phase 3 clinical trials, IV-to-oral switch and oral-only administration of omadacycline achieved the primary end points of noninferiority compared with linezolid in treating patients with ABSSSI
%K acute bacterial skin and skin structure
%K aminomethylcycline
%K antibiotics
%K cost-savings
%K economic modeling
%K hospitalized patients
%K hospital stay
%K infections
%K inpatient cost
%K intravenous
%K omadacycline
%K outpatient cost
%K skin infections
%K vancomycin
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322591/